- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed.
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Vigil Neuroscience (NASDAQ:VIGL – Free Report) had its target price decreased by Mizuho from $15.00 to $13.00 in a report issued on Thursday morning, FlyOnTheWall reports. Vigil Neuroscience Stock Performance NASDAQ VIGL opened at $6.72 on Thursday. The stock has a fifty day moving average of $8.81 and a 200-day moving average of $9.71. The […]
FY2026 EPS Estimates for Vigil Neuroscience, Inc Cut by Analyst (NASDAQ:VIGL) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $24.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 261.45% from the company’s current price. HC Wainwright also issued […]